Press Releases

07.26.2010
Cellceutix Corporation Selects Destum Partners to Partner Psoriasis Compound 07.07.2010
Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Required by FDA Prior to Filing Investigational New Drug (IND) Application 06.23.2010
Cellceutix Autism Research Demonstrates Increase in Serotonin Levels in Three Areas of the Brain 06.21.2010
Kevetrin Demonstrates Significant Results in the Treatment of Multi-Drug Resistant Cancer Cells 06.14.2010
New Autism Drug Research by Cellceutix on Compound KM-391 Results in Significant Behavioral Changes; Chief Scientific Officer Sees Potential for Company to Emerge as Industry Leader as Pharmas Strive for Revolutionary Autism Treatments 06.07.2010
Cellceutix Responds to Public Support by Expediting Autism Studies; Completes Two Required Safety Pharmacology Studies for Its Cancer Compound 06.03.2010
Cellceutix CFO Discusses Autism Drug, Kevetrin™ and Company Progressions with CEOCFO Interviews and News 05.28.2010
Cellceutix Signs Agreements for Kevetrin(TM) Phase 1 Support-Company Continues to Advance Kevetrin Toward Human Studies Targeting Drug Resistant Cancers 05.18.2010
Cellceutix Files Foreign Patent Application in PCT and Other Key Countries for Its Flagship Cancer Compound 05.13.2010
Recent Announcements Suggest Cellceutix Is Well Positioned With Autism Compound; Pfizer and Novartis Announcements Indicate Interest in Autism by Major Companies 04.21.2010
Cellceutix Presents Poster Session at AACR; Important New Data on Kevetrin(TM) in Resistant Lung Cancer Model Show Dose Response; No Tumor Cell Resistance With Second Cycle 04.13.2010
Cellceutix at AACR 04.12.2010
Cellceutix Ceo Appears On ‘Stu Taylor On Business’: Cancer And Autism Compounds Are Discussed 03.29.2010
Cellceutix Announces Positive Results With Autism Compound, KM-391 Showing Significant Improvements On Key Parameters In Animal Studies 03.22.2010
Cellceutix Signs Agreement for Kevetrin(TM) Formulation With Formatech 03.15.2010
Cellceutix Abstract Accepted by AACR 02.18.2010
Cellceutix Completes Successful Pre-IND Meeting With FDA for Cancer Drug 11.02.2009
Cellceutix Signs Agreement for Kevetrin(TM) Safety Studies with Toxikon Corporation 10.13.2009
Dr. Menon Selected For Expert Panel 10.06.2009
Cellceutix Compound Shows Significant Effect On Psoriasis

Latest News

06.03.2010

CEOCFO Interviews: Interview with Leo Ehrlich, CFO. 04.12.2010

Listen to: Stu Taylor on Business, April 10, 2010 show 04.07.2010

The Salem News: Autism drug tested on rats 10.19.2009


Startup pharma company runs a tight ship on path to crucial human testing 10.06.2009

Interview with George Evans, Cellceutix's CEO, at SmallCapVoice.com 10.06.2009

Breast Cancer Awareness Month Draws Investors Too 09.11.2009



Girindus America will manufacture the API for Cellceutix Corp's Kevetrin product 09.09.2009



IFCR in pact for collaborative research 08.25.2009



Cellceutix Corporation has acquired the rights to the blood pressure compound KM 732 08.20.2009



Cellceutix signs agreement with Girindus America 05.21.2009



Cellceutix Files Patent Application For Its Cancer Compound 05.14.2008



Cellceutix Obtains Initial Funding to Advance Its Head and Neck Cancer Drug